A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas - Wikidata - awgldk - TriplyDB

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

http://www.wikidata.org/entity/Q33434752

about

Recent advances of highly selective CDK4/6 inhibitors in breast cancer CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer.Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of action, Clinical Activity, and Safety Profiles.Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.Inhibitors of cyclin-dependent kinases as cancer therapeutics.The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Reviving the guardian of the genome: Small molecule activators of p53.Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib.Drug Monographs: Avelumab and Ribociclib.A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas.Clinical and Molecular Spectrum of Liposarcoma.Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer.CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation.Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.New agents for the management of resistant metastatic breast cancer.Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib.Complete Response to Single-agent Palbociclib in Metastatic Breast Cancer: A Case Report.Cell cycle regulation and anticancer drug discovery.Phase I study of single-agent ribociclib in Japanese patients with advanced solid tumors.Cell Cycle Regulation in Treatment of Breast Cancer.Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer.Cell-Cycle Therapeutics Come of Age.Ribociclib: First Global Approval.Development and validation of LC-MS/MS methods for the measurement of ribociclib, a CDK4/6 inhibitor, in mouse plasma and Ringer's solution and its application to a cerebral microdialysis study.Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF V600E -mutant melanoma.Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib.Deciphering the binding behavior of flavonoids to the cyclin dependent kinase 6/cyclin D complex.The role of abemaciclib in treatment of advanced breast cancer.Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer Profile of abemaciclib and its potential in the treatment of breast cancer A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

P2860

Q33602076-AF21B089-C645-413A-9548-7A8AEA290B38 Q33614544-F96FF0EE-A641-422B-AC48-AD44DA97C4A9 Q38649485-79DB1620-1551-4E1F-A04A-4619D3084E50 Q38662999-F5BCA529-36A3-4F5E-9BCB-816A2F824B63 Q38866877-DBC77A91-BEA2-490F-9A07-C8BC3D41C2BA Q38870282-F04401AC-48FC-4D8B-8DAB-2E2885C451C1 Q39125016-4AA15E0C-56B7-4EA2-883B-557D2E49E141 Q39183079-3EB847B6-8F42-4BD5-AC2C-396C2DC2B6FE Q39204274-7854AA15-D384-4314-A822-87BE6B48D9E4 Q39205536-E76B5701-7624-4C67-A50C-156EEA4F4F59 Q39232374-91070D9E-89C3-4190-9A4E-B9401066D416 Q39289608-3B4E4A3B-655C-4C4F-BE9A-7E778DEF45DD Q47169141-914981E6-E865-4ADA-AED5-D18E85998BAC Q47185616-FF4FE377-5F3F-414A-9320-9858DEDF55A1 Q47239499-0CDC5B5A-4DC2-467E-904C-BC9E252D9CDA Q47315579-2CCAFCC2-A2BF-477D-B9F7-0C01F976D389 Q47316489-F9FAA384-7B80-4F7A-AE70-93D31A1A34EB Q47321026-1E0FB429-C107-465B-99EC-33E6A5CFD58B Q47443248-BC14DBF4-BFEF-4FC4-BDC2-043111225CE6 Q47850321-B0A97428-B599-4F7A-B5C4-58BCD03C9516 Q48240854-0277469E-478B-4650-8352-8267F9472D03 Q48523042-4F8E96B1-22E2-45C8-81E3-E74F80CDC18B Q49341306-71E74CFF-CBB1-4EFD-A120-E65ABB37EB17 Q49449591-8AB33E82-60BB-47ED-9C61-68B31487EB28 Q49532522-745DF2A7-179D-42F7-9B7E-2C2522CE3933 Q49544319-B9F95465-6B3E-42A2-8505-EE4AA362C9CB Q50333196-346E23CD-96D4-4355-8374-3625C432B289 Q50959563-1E6445F4-1167-409B-849F-FD1D01F5538A Q51052636-430A8D97-480A-418E-937C-2C860895E658 Q52094553-1A1187AC-8B71-48FE-A032-50213A34D937 Q52655061-9A89B56D-9243-4EF6-B942-32D989EBDC4D Q53097644-10333374-5FFF-4194-ACED-C24CC5665816 Q54979952-3FB1E673-FFD8-40D7-994B-36CCDFE32358 Q55124984-3E41E2A0-6EC4-4370-A60A-90BAC6E129B8 Q57106504-FD2491A7-FE9E-451D-824A-6BFA5C167C6D Q57107448-FD44AC21-9525-4289-9081-9C6C6B87B8D8 Q58700136-9ADD432E-33B0-44F2-B2DD-A49A098F01C9 Q59137799-E596810D-061B-42D4-BF0B-E721811887DC

P2860

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

http://www.wikidata.org/entity/Q33434752

description

2016 nî lūn-bûn

@nan

2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

A Phase I Study of the Cyclin- ...... ced Solid Tumors and Lymphomas

@ast

A Phase I Study of the Cyclin- ...... ced Solid Tumors and Lymphomas

@en

type

label

A Phase I Study of the Cyclin- ...... ced Solid Tumors and Lymphomas

@ast

A Phase I Study of the Cyclin- ...... ced Solid Tumors and Lymphomas

@en

prefLabel

A Phase I Study of the Cyclin- ...... ced Solid Tumors and Lymphomas

@ast

A Phase I Study of the Cyclin- ...... ced Solid Tumors and Lymphomas

@en

P1433

Q33434752-78370203-0A95-457A-80FD-ABDD83D6411C

P1476

Q33434752-B9BA90CB-959C-4F56-8D78-B9317AFE82F9

P2093

Q33434752-05C0FF5E-6DAB-48A5-9F51-82DA7DB1DFB3

Q33434752-1FEA4735-18F1-44FC-B1D5-AC7E09EA3320

Q33434752-26AB49DF-0591-4AB7-9EFC-8B2A79FD5152

Q33434752-2BD6F50D-280F-4524-A013-1F814C3D26BC

Q33434752-35CA5137-698E-4E95-A652-E8F2C55244BB

Q33434752-362C2849-8F1B-45F0-B7F7-8617F7A51C09

Q33434752-4CC0E90E-7F06-485C-8F56-9EFDAB9025F9

Q33434752-85FE0546-AC8F-4840-8A88-FE01C1C31F78

Q33434752-B2A640AB-A1B3-4027-B1EA-D8A6F5B51A17

Q33434752-B85B7E85-797C-4D92-83F6-1A69D65C92E3

P2860

Q33434752-096D599B-4DA3-4628-BC3F-2C76B5FEF9A7

Q33434752-0B5320A0-EA64-4197-919E-96CFA8221AE3

Q33434752-24106458-0AA5-402A-8144-5BC0B8599AF0

Q33434752-28D3E44E-DEA4-4B7B-863A-C84D3A7CCACC

Q33434752-372565CB-153A-4505-9A9E-F267B789D11C

Q33434752-3B5BB349-AE4F-43EC-9F74-18DAC775023A

Q33434752-4357321A-C5AC-4345-8F5D-546179244045

Q33434752-706BAB18-8A48-4BC1-97FD-57E727479197

Q33434752-83511985-5913-4636-8AAF-2386CAAB4C68

Q33434752-85F83236-CF0D-4DCE-B24B-E3EAB131A142

P304

Q33434752-B1B9413E-D43C-4B02-8EFB-496B606B5586

P31

Q33434752-4EBD2D11-F3A0-4B21-BC75-1E45D7573097

P356

Q33434752-2CBC692C-E704-40D4-8A3D-DCB7DB91C681

P407

Q33434752-226D6105-DC5D-48DA-90C6-459D71430BED

P433

Q33434752-388EB524-8563-4643-9BA0-D156193E9A73

P478

Q33434752-B1801C46-32CF-4E8D-8AC3-0473A1F95342

P577

Q33434752-71E6EA38-A640-47ED-92DB-34FB05AC6A28

P698

Q33434752-D51F62A6-4819-410A-8845-5910C712F7F3

P932

Q33434752-B86C13D5-5F24-4FC6-BC93-3D9AC322D498

P356

1078-0432.CCR-16-1248

P1433

Clinical Cancer Research

P1476

A Phase I Study of the Cyclin- ...... ced Solid Tumors and Lymphomas

@en

P2093

Abhijit Chakraborty

http://www.w3.org/2001/XMLSchema#string

Adam S Crystal

http://www.w3.org/2001/XMLSchema#string

Alessandro Matano

http://www.w3.org/2001/XMLSchema#string

Geoffrey I Shapiro

http://www.w3.org/2001/XMLSchema#string

Jason R Dobson

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Infante

http://www.w3.org/2001/XMLSchema#string

John F Gerecitano

http://www.w3.org/2001/XMLSchema#string

Petronella O Witteveen

http://www.w3.org/2001/XMLSchema#string

Philippe A Cassier

http://www.w3.org/2001/XMLSchema#string

Rashmi Chugh

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Targeting CDK4 and CDK6: From Discovery to Therapy

Role of the p16 tumor suppressor gene in cancer

Cyclin-dependent kinase pathways as targets for cancer treatment

Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Update on the therapeutic potential of PDE4 inhibitors.

The history and future of targeting cyclin-dependent kinases in cancer therapy.

P304

5696-5705

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-16-1248

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27542767

http://www.w3.org/2001/XMLSchema#string

P932

5621377

http://www.w3.org/2001/XMLSchema#string